These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35798765)

  • 1. Anti-neoplastic action of Cimetidine/Vitamin C on histamine and the PI3K/AKT/mTOR pathway in Ehrlich breast cancer.
    Ibrahim SSA; El-Aal SAA; Reda AM; Achy SE; Shahine Y
    Sci Rep; 2022 Jul; 12(1):11514. PubMed ID: 35798765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
    Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperine enhances doxorubicin sensitivity in triple-negative breast cancer by targeting the PI3K/Akt/mTOR pathway and cancer stem cells.
    Hakeem AN; El-Kersh DM; Hammam O; Elhosseiny A; Zaki A; Kamel K; Yasser L; Barsom M; Ahmed M; Gamal M; Attia YM
    Sci Rep; 2024 Aug; 14(1):18181. PubMed ID: 39107323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.
    Du L; Li X; Zhen L; Chen W; Mu L; Zhang Y; Song A
    Mol Med Rep; 2018 May; 17(5):7163-7169. PubMed ID: 29568883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton.
    Zhang C; Yang N; Yang CH; Ding HS; Luo C; Zhang Y; Wu MJ; Zhang XW; Shen X; Jiang HL; Meng LH; Ding J
    PLoS One; 2009; 4(3):e4881. PubMed ID: 19293927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway.
    Yan X; Hui Y; Hua Y; Huang L; Wang L; Peng F; Tang C; Liu D; Song J; Wang F
    Biomed Pharmacother; 2019 Jan; 109():762-769. PubMed ID: 30551529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
    Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway.
    Zhang H; Xu HL; Wang YC; Lu ZY; Yu XF; Sui DY
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29614812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer.
    Moench R; Grimmig T; Kannen V; Tripathi S; Faber M; Moll EM; Chandraker A; Lissner R; Germer CT; Waaga-Gasser AM; Gasser M
    Oncotarget; 2016 Oct; 7(42):68749-68767. PubMed ID: 27626684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
    Polo ML; Riggio M; May M; Rodríguez MJ; Perrone MC; Stallings-Mann M; Kaen D; Frost M; Goetz M; Boughey J; Lanari C; Radisky D; Novaro V
    Oncotarget; 2015 Sep; 6(26):22081-97. PubMed ID: 26098779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
    Bian P; Hu W; Liu C; Li L
    Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway.
    Zhou R; Chen H; Chen J; Chen X; Wen Y; Xu L
    BMC Complement Altern Med; 2018 Mar; 18(1):83. PubMed ID: 29523109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway.
    Wang S; Zhang Y; Ren T; Wu Q; Lu H; Qin X; Liu Y; Ding H; Zhao Q
    Cell Death Dis; 2020 Jun; 11(6):491. PubMed ID: 32606352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti‑cancer effects of fisetin on mammary carcinoma cells via regulation of the PI3K/Akt/mTOR pathway: In vitro and in vivo studies.
    Sun X; Ma X; Li Q; Yang Y; Xu X; Sun J; Yu M; Cao K; Yang L; Yang G; Zhang G; Wang X
    Int J Mol Med; 2018 Aug; 42(2):811-820. PubMed ID: 29749427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Mangostin inhibits DMBA/TPA-induced skin cancer through inhibiting inflammation and promoting autophagy and apoptosis by regulating PI3K/Akt/mTOR signaling pathway in mice.
    Wang F; Ma H; Liu Z; Huang W; Xu X; Zhang X
    Biomed Pharmacother; 2017 Aug; 92():672-680. PubMed ID: 28582759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
    El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
    Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.